Constrained Optimization for Pneumococcal Vaccination in Brazil

Constrained Optimization for Pneumococcal Vaccination in Brazil

Objectives: To identify the most cost-efficient combination of pneumococcal vaccines in infants and aging adults for a 10-year period in Brazil. Methods: Constrained optimization (CO) prioritized 9 pneumococcal vaccine regimens according to their gain in quality-adjusted life-years (QALYs) and their...

Full description

Bibliographic Details
Main Authors:	Gomez, J.A (Author), Olbrecht, J. (Author), Standaert, B. (Author), Van Bellinghen, L.-A (Author), Van Vlaenderen, I. (Author)
Format:	Article
Language:	English
Published:	Elsevier Inc. 2021
Subjects:	adolescent adult Adult aged Article Brazil budget child cohort analysis controlled study cost effectiveness analysis drug efficacy economic evaluation epidemiological data Haemophilus influenzae vaccine health care cost herd immunity high risk population human Humans infant Infant investment optimization pneumococcal infection Pneumococcal Infections pneumococcal vaccination Pneumococcal Vaccines Pneumococcus vaccine priority journal process optimization quality adjusted life year scoring system vaccination Vaccination vaccine Vaccines, Conjugate
Online Access:	View Fulltext in Publisher

Similar Items

Vaccination against pneumococcal infections in adults
by: Kozlov R.S., et al.
Published: (2018-02-01)

Vaccine Prevention of Pneumococcal Infection in Children
by: Alexander A. Baranov, et al.
Published: (2018-07-01)

Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada
by: Earnshaw Stephanie R, et al.
Published: (2012-04-01)

Rationale and methods of a randomized controlled trial of immunogenicity, safety and impact on carriage of pneumococcal conjugate and polysaccharide vaccines in infants in Papua New Guinea
by: Deborah Lehmann, et al.
Published: (2017-12-01)

Vaccinal Prevention of Pneumococcal Infection in Children
by: A. A. Baranov, et al.
Published: (2015-12-01)

Effects of Pneumococcal Conjugate Vaccine 2 Years after Its Introduction, the Netherlands
by: Gerwin D. Rodenburg, et al.
Published: (2010-05-01)

Efficacy and effectiveness of extended-valency pneumococcal conjugate vaccines
by: Hyunju Lee, et al.
Published: (2014-02-01)

Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy
by: Filippo Ansaldi, et al.
Published: (2020-01-01)

CLINICAL AND EPIDEMIOLOGICAL ASSESSMENT OF THE EFFECTIVENESS OF VACCINATION OF CHILDREN AGAINST PNEUMOCOCCAL INFECTION IN THE AMUR REGION
by: A. G. Chuchalin, et al.
Published: (2016-06-01)

NEXT GENERATION PNEUMOCOCCAL CONJUGATE VACCINES EFFICACY AND EFFECTIVENESS IN DIFFERENT REGIONS OF THE WORLD
by: O. P. Kovtun, et al.
Published: (2014-01-01)

Seven-Valent Pneumococcal Conjugate Vaccine and Nasopharyngeal Microbiota in Healthy Children
by: Giske Biesbroek, et al.
Published: (2014-02-01)

VACCINATION AGAINST PNEUMOCOCCAL INFECTIONS IN RUSSIAN FEDERATION: SOCIAL AND PHARMACOECONOMIC ASPECTS
by: A. V. Rudakova, et al.
Published: (2018-10-01)

Vaccination as a solution of the issue of resistance S. pneumoniae
by: H. P. Ruban, et al.
Published: (2021-05-01)

Cost-effectiveness of vaccination against pneumococcal infection of adults at risk within the federal and regional programs
by: A. V. Rudakova, et al.
Published: (2019-12-01)

EXPERIENCE OF APPLICATION AND SAFETY ASSESSMENT OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN UNDER-5 CHILDREN
by: M. V. Fedoseenko, et al.
Published: (2014-09-01)

Is 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Combined With 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) Superior to PPSV23 Alone for Reducing Incidence or Severity of Pneumonia in Older Adults? A Clin-IQ
by: Starla Hayward, et al.
Published: (2016-04-01)

VACCINE PREVENTION OF PNEUMOCOCCAL INFECTIONS IN ADULTS
by: A. A. Zaitsev, et al.
Published: (2017-11-01)

Effectiveness of Vaccination against Pneumococcal Infection in Uzbekistan: a Preliminary Assessmant and Prognosis
by: T. A. Daminov, et al.
Published: (2018-12-01)

Immunological and Epidemiological Aspects of the Immunogenicity of Streptococcus Pneumoniae Serotype 3 Capsular Polysaccharide in Pneumococcal Vaccines
by: A. E. Zaitsev, et al.
Published: (2020-04-01)

The Analysis of Scientific Data on the Efficacy of Pneumococcal Conjugated Vaccine in the Cohort of Children with Bronchial Asthma
by: Tatiana A. Kaliuzhnaia, et al.
Published: (2020-11-01)

Parental knowledge, attitudes and perception of pneumococcal disease and pneumococcal conjugate vaccines in Singapore: a questionnaire-based assessment
by: Choon How How, et al.
Published: (2016-09-01)

Pneumococcal and Influenza Vaccination Coverage Rates of Adult Patients at Risk and Their Attitudes Towards Vaccination
by: Lale ÖZIŞIK, et al.
Published: (2016-03-01)

Modern approaches to the prevention of pneumococcal infection
by: S. M. Kharit, et al.
Published: (2015-12-01)

Antibody response to 13-valent pneumococcal conjugate vaccine is not impaired in patients with rheumatoid arthritis or primary Sjögren’s syndrome without disease modifying treatment
by: Per Nived, et al.
Published: (2018-04-01)

August 2013 pulmonary journal club: pneumococcal vaccine déjà vu
by: Robbins RA
Published: (2013-08-01)

Pneumonia: Regional experience with prevention programs
by: A G Chuchalin, et al.
Published: (2016-08-01)

Seasonal influenza and pneumococcal vaccination in institutionalized older adults
by: Chan, Tuen-ching, et al.
Published: (2015)

Modern Approaches to Vaccinal Prevention of a Pneumococcal Infection in Adults Patients with Diabetes Mellitus (Literature Review)
by: J. A. Paramonova, et al.
Published: (2018-04-01)

Meeting the challenge: prevention of pneumococcal disease with conjugate vaccines
by: Echániz-Avilés Irma Gabriela, et al.
Published: (2001-01-01)

Changes in Childhood Pneumonia Hospitalizations by Race and Sex Associated with Pneumococcal Conjugate Vaccines
by: Andrew D. Wiese, et al.
Published: (2016-06-01)

Prevention of Community-Acquired Pneumonia with Available Pneumococcal Vaccines
by: Nicola Principi, et al.
Published: (2016-12-01)

Economic evaluation of the second generation pneumococcal conjugate vaccine in children : a systematic review
by: Fan, Hiu-yan, et al.
Published: (2014)

The cost-effectiveness of 13-valent pneumococcal conjugate vaccine for older adults : a systematic review
by: Wong, Kwan-ting, et al.
Published: (2014)

Invasive pneumococcal disease in persons with predisposing factors is dominated by non-vaccine serotypes in Southwest Sweden
by: Karin Bergman, et al.
Published: (2021-08-01)

Individual protection and population effect – two sides of one medal
by: G. L. Ignatova, et al.
Published: (2018-10-01)

Vaccination against Pneumococcal Infections of High-Risk People: Pharmacoeconomic Aspects
by: A. V. Rudakova, et al.
Published: (2020-01-01)

PROPHYLACTIC EFFICACY OF VACCINATION AGAINST PNEUMOCOCCAL INFECTION IN CHILDREN WITH CHRONIC ADENOTONSILLAR DISEASES
by: S. N. Beniova, et al.
Published: (2015-08-01)

EFFECTIVENESS OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE: EMERGING DATA FROM INVASIVE PNEUMOCOCCAL DISEASE, PNEUMONIA, ACUTE OTITIS MEDIA AND NASOPHARYNGEAL CARRIAGE
by: Ralf Rene Reinert, et al.
Published: (2012-06-01)

Pneumococcal conjugate 7-valent vacciPNEUMOCOCCAL CONJUGATE 7-VALENT VACCINE IN CHILDREN. REGIONAL EXPERIENCEne in children. Regional experience
by: N. L. Chernaya, et al.
Published: (2012-02-01)

Recommendation for use of the newly introduced pneumococcal protein conjugate vaccines in Korea
by: Eun Hwa Choi, et al.
Published: (2011-04-01)